{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:44:08Z","timestamp":1793324648205,"version":"4.5.0"},"reference-count":51,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA201036"],"award-info":[{"award-number":["CA201036"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CCSG","award":["2P30CA016058"],"award-info":[{"award-number":["2P30CA016058"]}]},{"name":"NIH","award":["2T32CA09223-16A1"],"award-info":[{"award-number":["2T32CA09223-16A1"]}]},{"name":"NIH","award":["P01CA278732"],"award-info":[{"award-number":["P01CA278732"]}]},{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["OSU-PSSR 2021259"],"award-info":[{"award-number":["OSU-PSSR 2021259"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,9,7]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer is unique among visceral malignancies in that urine, which can be easily obtained, has prolonged contact with bladder tumors. Urinary biomarkers offer the potential to provide insight into the host and tumor immune microenvironment to guide therapeutic strategies. We evaluated the immune cellular composition of urine (urine-derived lymphocytes (UDLs)) versus tumor (tumor-infiltrating lymphocytes (TILs)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We employed high-dimensional flow cytometry analyses on immune cells from tumors (TILs), urine (UDLs), and peripheral blood (peripheral blood mononuclear cells) among patients with bladder cancer. We performed multiplexed immunofluorescence (mIF) of matched tumors to provide spatial context to our findings, comparing deep\/invasive and superficial\/urine-facing regions of matched tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Our findings suggest that the CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell subsets of UDLs characterized by flow cytometry had similar phenotypic profiles to those found in TILs (cell clusters quantified by multidimensional scaling and differentiation states). Results of mIF imaging with a panel of phenotypic and functional T cell markers suggested that UDLs reflected TILs in both superficial and deep tumor sections. We also found sex-dependent patterns in TILs and UDLs, indicating the male bladder cancer tumor microenvironment is enriched in exhausted CD4\n                      <jats:sup>+<\/jats:sup>\n                      and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells, while the female bladder cancer microenvironment is enriched for activated T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Assessment of UDLs opens avenues of non-invasive biomarker development in clinical settings where bladder cancer TILs are hypothesized to predict clinical response. UDLs may also reflect sex-based differences in antitumor immunity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012050","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T06:55:16Z","timestamp":1759474516000},"page":"e012050","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs and reflect immunological sex differences in bladder cancer"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct02891161","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05521698","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-5621","authenticated-orcid":false,"given":"Johanna M","family":"Schafer","sequence":"first","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Roche Diagnostics Solutions, Oro Valley, Arizona, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0947-0597","authenticated-orcid":false,"given":"No-Joon","family":"Song","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Xiao","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy D","family":"Gauntner","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyeong Joo","family":"Jung","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Computer Science, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9211-4300","authenticated-orcid":false,"given":"Emily G","family":"Fitts","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishan","family":"Kumar","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeong Seon","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Computer Science, The Ohio State University, Columbus, Ohio, USA"},{"name":"University of Houston, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan A","family":"Elaoud","sequence":"additional","affiliation":[{"name":"The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsi","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent M","family":"Caruso","sequence":"additional","affiliation":[{"name":"Convergent Genomics Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor G","family":"Levin","sequence":"additional","affiliation":[{"name":"Convergent Genomics Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McConkey","sequence":"additional","affiliation":[{"name":"Johns Hopkins Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl T","family":"Lee","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Urology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal S","family":"Pohar","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Urology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K","family":"Clinton","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Carson","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8072-5671","authenticated-orcid":false,"given":"Dongjun","family":"Chung","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Biomedical Informatics, The Ohio State University College of Medicine, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-927X","authenticated-orcid":false,"given":"Zihai","family":"Li","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6980-4777","authenticated-orcid":false,"given":"Debasish","family":"Sundi","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA"},{"name":"Pelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, Ohio, USA"},{"name":"Department of Urology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"2025111301350728000_13.10.e012050.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpi.2022.100105"},{"key":"2025111301350728000_13.10.e012050.2","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ucl.2022.09.009","article-title":"Urine-Based Markers for Detection of Urothelial Cancer and for the Management of Non-muscle-Invasive Bladder Cancer","volume":"50","author":"Lotan","year":"2023","journal-title":"Urol Clin North Am"},{"key":"2025111301350728000_13.10.e012050.3","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1158\/1078-0432.CCR-23-0570","article-title":"Development and Multicenter Case-Control Validation of Urinary Comprehensive Genomic Profiling for Urothelial Carcinoma Diagnosis, Surveillance, and Risk-Prediction","volume":"29","author":"Salari","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025111301350728000_13.10.e012050.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41698-022-00345-w","article-title":"Urine cell-free DNA multi-omics to detect MRD and predict survival in bladder cancer patients","volume":"7","author":"Chauhan","year":"2023","journal-title":"NPJ Precis Oncol"},{"key":"2025111301350728000_13.10.e012050.5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.eururo.2022.08.011","article-title":"BlaDimiR: A Urine-based miRNA Score for Accurate Bladder Cancer Diagnosis and Follow-up","volume":"82","author":"Suarez-Cabrera","year":"2022","journal-title":"Eur Urol"},{"key":"2025111301350728000_13.10.e012050.6","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.eururo.2015.06.023","article-title":"Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Kamat","year":"2016","journal-title":"Eur Urol"},{"key":"2025111301350728000_13.10.e012050.7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20181003"},{"key":"2025111301350728000_13.10.e012050.8","doi-asserted-by":"crossref","first-page":"14244","DOI":"10.1038\/s41598-021-93754-z","article-title":"Detection of PD-L1 in the urine of patients with urothelial carcinoma of the bladder","volume":"11","author":"Tosev","year":"2021","journal-title":"Sci Rep"},{"key":"2025111301350728000_13.10.e012050.9","doi-asserted-by":"crossref","first-page":"970931","DOI":"10.3389\/fimmu.2022.970931","article-title":"CyTOF analysis identifies unusual immune cells in urine of BCG-treated bladder cancer patients","volume":"13","author":"Castellano","year":"2022","journal-title":"Front Immunol"},{"key":"2025111301350728000_13.10.e012050.10","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20240045","article-title":"Urine scRNAseq reveals new insights into the bladder tumor immune microenvironment","volume":"221","author":"Tran","year":"2024","journal-title":"J Exp Med"},{"key":"2025111301350728000_13.10.e012050.11","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abq2630","article-title":"Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer","volume":"7","author":"Kwon","year":"2022","journal-title":"Sci Immunol"},{"key":"2025111301350728000_13.10.e012050.12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-3020-4_1","article-title":"Development of Spectral Imaging Cytometry. Spectral and Imaging Cytometry","volume":"2635","author":"Vorobjev","year":"2023","journal-title":"Methods Mol Biol"},{"key":"2025111301350728000_13.10.e012050.13","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1466","article-title":"Design, optimisation and standardisation of a high-dimensional spectral flow cytometry workflow assessing T-cell immunophenotype in patients with melanoma","volume":"12","author":"Edwards","year":"2023","journal-title":"Clin Transl Immunology"},{"key":"2025111301350728000_13.10.e012050.14","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s00262-019-02372-2","article-title":"An IL-15-based superagonist ALT-803 enhances the NK cell response to cetuximab-treated squamous cell carcinoma of the head and neck","volume":"68","author":"Pinette","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"2025111301350728000_13.10.e012050.15","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-10-145","article-title":"flowClust: a Bioconductor package for automated gating of flow cytometry data","volume":"10","author":"Lo","year":"2009","journal-title":"BMC Bioinformatics"},{"key":"2025111301350728000_13.10.e012050.16","unstructured":"Kolde R . Package \u201cpheatmap\u201d: Pretty Heatmaps. 2019."},{"key":"2025111301350728000_13.10.e012050.17","doi-asserted-by":"publisher","DOI":"10.21105\/joss.00861"},{"key":"2025111301350728000_13.10.e012050.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12864-018-4772-0","article-title":"Slingshot: cell lineage and pseudotime inference for single-cell transcriptomics","volume":"19","author":"Street","year":"2018","journal-title":"BMC Genomics"},{"key":"2025111301350728000_13.10.e012050.19","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2025111301350728000_13.10.e012050.20","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11195827","article-title":"Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention","volume":"11","author":"Bicocca","year":"2022","journal-title":"J Clin Med"},{"key":"2025111301350728000_13.10.e012050.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-018-1568-0","article-title":"KrakenUniq: confident and fast metagenomics classification using unique k-mer counts","volume":"19","author":"Breitwieser","year":"2018","journal-title":"Genome Biol"},{"key":"2025111301350728000_13.10.e012050.22","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2025111301350728000_13.10.e012050.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2023.113459"},{"key":"2025111301350728000_13.10.e012050.24","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41585-022-00591-4","article-title":"Sex differences in bladder cancer: emerging data and call to action","volume":"19","author":"Theodorescu","year":"2022","journal-title":"Nat Rev Urol"},{"key":"2025111301350728000_13.10.e012050.25","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/s41586-023-06234-x","article-title":"Y chromosome loss in cancer drives growth by evasion of adaptive immunity","volume":"619","author":"Abdel-Hafiz","year":"2023","journal-title":"Nature New Biol"},{"key":"2025111301350728000_13.10.e012050.26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2024.01.004","article-title":"The Elusive Horizon: Biomarkers in Urothelial Carcinoma","volume":"85","author":"Linscott","year":"2024","journal-title":"Eur Urol"},{"key":"2025111301350728000_13.10.e012050.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"2025111301350728000_13.10.e012050.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"2025111301350728000_13.10.e012050.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.08.016"},{"key":"2025111301350728000_13.10.e012050.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"2025111301350728000_13.10.e012050.31","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"Bladder Cancer, Version 2.2022 Featured Updates to the NCCN Guidelines","volume":"20","author":"Flaig","year":"2022","journal-title":"JNCCN Journal of the National Comprehensive Cancer Network"},{"key":"2025111301350728000_13.10.e012050.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"key":"2025111301350728000_13.10.e012050.33","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003846"},{"key":"2025111301350728000_13.10.e012050.34","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-37568-9","article-title":"Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer","volume":"14","author":"Robertson","year":"2023","journal-title":"Nat Commun"},{"key":"2025111301350728000_13.10.e012050.35","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025111301350728000_13.10.e012050.36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/jnci\/djaa076","article-title":"Predicting the Pathologic Complete Response After Neoadjuvant Pembrolizumab in Muscle-Invasive Bladder Cancer","volume":"113","author":"Bandini","year":"2021","journal-title":"JNCI"},{"key":"2025111301350728000_13.10.e012050.37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01148"},{"key":"2025111301350728000_13.10.e012050.38","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.eururo.2022.09.008","article-title":"Elevated T-cell Exhaustion and Urinary Tumor DNA Levels Are Associated with Bacillus Calmette-Gu\u00e9rin Failure in Patients with Non-muscle-invasive Bladder Cancer","volume":"82","author":"Strandgaard","year":"2022","journal-title":"Eur Urol"},{"key":"2025111301350728000_13.10.e012050.39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1700380"},{"key":"2025111301350728000_13.10.e012050.40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003732","article-title":"Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study","volume":"18","author":"Chauhan","year":"2021","journal-title":"PLoS Med"},{"key":"2025111301350728000_13.10.e012050.41","unstructured":"Chaudhuri AA , Pellini B , Pejovic N , et al . Emerging Roles of Urine-Based Tumor DNA Analysis in Bladder Cancer Management. 2024."},{"key":"2025111301350728000_13.10.e012050.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-017-0099-6"},{"key":"2025111301350728000_13.10.e012050.43","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121062","article-title":"CD4+ T cells induce rejection of urothelial tumors after immune checkpoint blockade","volume":"3","author":"Sato","year":"2018","journal-title":"JCI Insight"},{"key":"2025111301350728000_13.10.e012050.44","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms3209","article-title":"Highly self-reactive naive CD4 T cells are prone to differentiate into regulatory T cells","volume":"4","author":"Martin","year":"2013","journal-title":"Nat Commun"},{"key":"2025111301350728000_13.10.e012050.45","doi-asserted-by":"crossref","unstructured":"Sundi D , Collier KA , Yang Y , et al . Roles of Androgen Receptor Signaling in Urothelial Carcinoma. Cancers (Basel) 2024;16. doi:10.3390\/cancers16040746","DOI":"10.3390\/cancers16040746"},{"key":"2025111301350728000_13.10.e012050.46","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(18)30445-5","article-title":"Sex as a predictor of response to cancer immunotherapy","volume":"19","author":"Kwon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2025111301350728000_13.10.e012050.47","doi-asserted-by":"publisher","DOI":"10.1177\/1753425912463618"},{"key":"2025111301350728000_13.10.e012050.48","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1097\/JU.0000000000001878","article-title":"Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer","volume":"206","author":"Zhang","year":"2021","journal-title":"J Urol"},{"key":"2025111301350728000_13.10.e012050.49","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1158\/1078-0432.CCR-23-0513","article-title":"Urinary Tumor DNA MRD Analysis to Identify Responders to Neoadjuvant Immunotherapy in Muscle-invasive Bladder Cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025111301350728000_13.10.e012050.50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0825"},{"key":"2025111301350728000_13.10.e012050.51","doi-asserted-by":"crossref","unstructured":"Joshi M , Tuanquin L , Zhu J , et al . Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: Results from phase II study,BTCRC-GU15-023. J Immunother Cance 2023;11. doi:10.1136\/jitc-2022-006551","DOI":"10.1136\/jitc-2022-006551"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:35:19Z","timestamp":1763026519000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":51,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/jitc-2025-012050"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012050","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}